Humanized FcγRIIB-specific antibodies and methods of use thereof
The present invention relates to humanized FcγRIIB antibodies, fragments, and variants thereof that bind human FcγRIIB with a greater affinity than said antibody binds FcγRIIA. The invention encompasses the use of the humanized antibodies of the invention for the treatment of any disease related to loss of balance of Fc receptor mediated signaling, such as cancer, autoimmune and inflammatory disease. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the humanized antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing the efficacy of a vaccine composition by administering the humanized antibodies of the invention. The invention encompasses methods for treating an autoimmune disease and methods for elimination of cancer cells that express FcγRIIB.
1. A humanized antibody or antigen binding fragment thereof that specifically binds to the extracellular domain of native human FcγRIIB with greater affinity than to the extracellular domain of native human FcγRIIA, wherein the humanized antibody or antigen binding fragment thereof comprises a heavy chain region having the amino acid sequence of SEQ ID NO. 24 and a light chain region having the amino acid sequence of SEQ ID NO. 22.
2. The humanized antibody fragment of claim 1 , wherein said fragment is a F(ab′)2 fragment or a F(ab) fragment.
3. The humanized antibody of claim 1 , wherein said antibody is a single chain antibody.
4. The humanized antibody of claim 1 , wherein said antibody is operably linked to a heterologous polypeptide.
5. The humanized antibody of claim 1 , wherein said antibody is conjugated to a therapeutic agent.
6. The humanized antibody of claim 5 , wherein said therapeutic agent is a cytotoxin.
7. The humanized antibody of claim 1 which blocks binding of an Ig-Fc to FcγRIIB.
8. A pharmaceutical composition comprising a therapeutically effective amount of the humanized antibody or antigen binding fragment thereof of claim 1 and a pharmaceutically acceptable carrier.